In this episode, I discuss the role that Canada played in developing and commercializing one of the world's most important biological weapons: the M.O.V. (memc-vaccine) delivery system for treating viruses such as HIV/AIDS, SARS, and other viral diseases.
00:00:00.560And according to Pfizer, we have what they refer to in their own documents as an acceptable death rate.
00:00:09.140I don't know how many of you can sit with that statement, but the notion that there is something called an acceptable death rate is something I find morally repugnant.
00:00:20.380But I find more interesting than that, Canada's role in this, which has achieved almost no fundamental coverage in any media or even in the counterculture media, and most Canadians don't realize that Canada itself, and not just Canada, but specifically the University of British Columbia, beginning in 2005, realized that if it was going to be relevant in the biotech space,
00:00:50.380it had to be the country, and it had to be the research hotbed for establishing the delivery mechanism whereby mRNA vaccines could be developed.
00:01:02.180The University of British Columbia, working in partnership with INEX Pharmaceuticals in 2005, developed the lipid nanoparticle technology that ultimately became the basis of the formation of a company in British Columbia called Techmera Pharmaceuticals.
00:01:18.140In 2009, Techmera had a very interesting set of challenges, and this was commensurate with the 2008 declaration by the World Health Organization that the coronavirus was in fact eradicated as a condition associated with SARS.
00:01:35.820And because of the lack of funding in 2008, both Canada and the United States struggled with the fact that they had developed a technology that was supposed to be for a vaccination of coronavirus and for a number of other viral models.
00:01:52.100But the problem was they ran out of funding, but the problem was they ran out of funding, and so there was a series of reorganizations, and in those reorganizations, two companies were formed, Arbutus Pharmaceuticals and Acuitus Pharmaceuticals.
00:02:05.300Acuitus is the one that, unfortunately, the government of Canada has not told the citizens of Canada is the reason why both Moderna and Pfizer have the ability to deliver the current bioweapons program.
00:02:20.960And I think most people would be shocked to find out that when you have the Prime Minister of Canada getting up in front of a camera in the spring of 2020 telling the world that the only way forward is to allegedly return to a new normal when there is a vaccine,
00:02:41.280what Trudeau did not tell the public, what Trudeau did not tell the public was that he had a financial stake in the outcome of that being the selected pathway forward.
00:02:51.280What he didn't tell the Canadian public was that Canada's blight on the moral record of what has been historically an amazingly wonderful set of innovations coming out of the Canadian research institutions and research laboratories,
00:03:09.460in fact created the mechanism whereby you could take mRNA and inject it into a population and try to stabilize that injection.
00:03:18.620The lipid nanoparticle technology that was developed and ultimately passed to Arbutus was the subject of a licensing agreement
00:03:26.460that was made with Acuitous pharmaceuticals in British Columbia private company who conveniently had very little reporting requirements
00:03:35.400and Acuitous misappropriated the lipid nanoparticle technology
00:03:41.080and ultimately made it available to both BioNTech and Moderna.
00:03:46.620It is absolutely critical for us to understand that without the Canadian contribution of the lipid nanoparticle technology from British Columbia,
00:03:56.640we would have no meaningful response in the form of what's being called a vaccination and we would not have a bioweapons program.
00:04:06.880That's a pretty important statement to make to an audience largely of Canadians.
00:04:10.820And it would be very interesting to find out why it is that Trudeau has not admitted to the public
00:04:18.380and has been unwilling to actually put into the public record the what we know to be at least billions of dollars of concessions.
00:04:29.740And it could be, I mean, if we look at just Pfizer-BioNTech's own situation,
00:04:35.040we know that in the case of Pfizer-BioNTech, that last quarter alone, somewhere between eight and nine billion dollars
00:04:44.200came in the form of the revenue off of all of the interventions that are being sold off as coronavirus vaccines.
00:04:54.740In the last quarter alone, this would place this tiny little British Columbia company,
00:05:00.080which in 2009, people, was functionally owned by one person.
00:05:05.500I mean, we need to kind of bear that in mind.
00:05:08.320One person actually owned this company, Thomas Madden, who's the CEO of Acuitous.
00:05:15.360In 2009, he was largely the sole owner of it.
00:05:19.860He actually appropriated the technology in a labor dispute,
00:05:23.760which functionally was a trade secret argument around this.
00:05:27.740And when we actually look at what happened in 2016,
00:05:31.480and this is a very important point, people.
00:05:33.680In 2016, somebody in Canada knew that there was something going to happen
00:05:39.820with this particular vaccine platform,